Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.

Abstract: Disclosed is a method of operating a terminal on which an application for an instant messaging service is installed, the method that displays a first user interface (UI) for switching an input mode in a chatting interface of a chatroom in which a user of the application is participating, based on whether the user is assigned an authority to emphasize a message in the chatroom, switches the input mode from a first mode which is a normal mode to a second mode for emphasizing a message, in response to a user input with respect to the first UI, emphasizes a message input in the second mode for a predetermined period in a predetermined manner, and cancels the emphasizing of the message input in the second mode, when the predetermined time elapses.

Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.

Abstract: The present invention relates to a novel variant RNA polymerase sigma factor 70 (?70) polypeptide, a polynucleotide encoding the same, a microorganism containing the polypeptide, and a method for producing L-threonine by using the microorganism.

Abstract: The present invention relates to an organic-inorganic hybrid nanoporous material, maintaining a nanoporous skeleton structure formed by coordination of an organic ligand containing an aromatic compound to a trivalent central metal ion, and further having an intramolecular acid anhydride functional group modified on the aromatic compound of the nanoporous skeleton structure, and thereby exhibits selectivity for olefins, and an adsorbent comprising the same. Specifically, the organic-inorganic hybrid nanoporous material of the present invention exhibits an excellent olefin-selective adsorption capacity through differences in adsorption equilibrium and adsorption rate, and thus can be usefully employed in the separation of C2-C4 hydrocarbons.

Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

Abstract: The present invention is a heat-resistant receptacle cap comprising: an inner cap 100 having an insertion pipe 120 configured to be fitted onto an inlet of a receptacle with a locking hook, a discharge gate 140 connected to the insertion pipe 120 with a small-diameter pipe 145 and formed so that contents in the receptacle is discharged at the small-diameter pipe 145, and a container 200 which is installed at the bottom of the small-diameter pipe 145 and has an open upper part to hold additives therein; a heat-resistant sealing plate 220 configured to heat-seal the insertion pipe 120 and upper wall of the container 200; a sealing plate holder 300 which is provided with a fitting ring 310 that fits the sealing plate 220 to a corresponding part for coupling the heat-resistant sealing plate 220, and which is fitted at an upper end of an inner side wall of an outer cap 400; and the outer cap 400 having a sealing plate holder fixing step 420 which is formed on a side wall 401 and configured to separate the seal

Abstract: The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.

Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.

Abstract: The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.

Abstract: Disclosed are a recombinant microorganism having enhanced L-amino acid producibility, wherein the recombinant microorganism is transformed to have an inactivated phage receptor thereof, and a method of producing an L-amino acid using the recombinant microorganism. The use of the recombinant microorganism may enable the production of the L-amino acid in a highly efficient manner.

Abstract: Disclosed are a recombinant microorganism having enhanced L-amino acid productivity, wherein the recombinant microorganism is transformed to have removed or decreased activity of at least one of adenosine deaminase and AMP nucleosidase, and a method of producing an L-amino acid using the recombinant microorganism. The use of the recombinant microorganism may enable the production of the L-amino acid in a highly efficient manner.

Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

Abstract: The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.

Abstract: The present invention relates to an E. coli mutant strain having enhanced L-threonine productivity, which is obtained by introducing the permease of Corynebacterium origin, and to method of producing L-threonine using the E. coli mutant strain.

Abstract: Disclosed are a message service provision method for providing a message service via an open chat room corresponding to link information, and a message server and a terminal for executing the message service provision method. The message service provision method comprises the steps of: transmitting, to a message server, a request for issuing link information for an open chat room via a message application; receiving, from the message server, link information generated in response to the request for issuing link information; sharing the link information according to a request for sharing inputted by a user of a host terminal; and performing chatting with a user of a guest terminal participating in the open chat room by means of the shared link information; wherein the user of the guest terminal and the user of the host terminal are users who subscribed to a message service provided via the message server.

Abstract: A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK? and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.

Abstract: An extreme ultraviolet (EUV) exposure system capable of improving the yield of an EUV exposure process by improving EUV exposure performance, and furthermore, capable of increasing throughput or productivity of the EUV exposure process, the EUV exposure system including an EUV exposure apparatus configured to perform EUV exposure on a wafer disposed on a chuck table, a load-lock chamber combined with the EUV exposure apparatus and configured to supply and discharge the wafer to/from the EUV exposure apparatus, and an ultraviolet (UV) exposure apparatus configured to perform UV exposure by irradiating an entire upper surface of the wafer with a UV light without using a mask.

Abstract: The present invention is a heat-resistant receptacle cap comprising: an inner cap 100 having an insertion pipe 120 configured to be fitted onto an inlet of a receptacle with a locking hook, a discharge gate 140 connected to the insertion pipe 120 with a small-diameter pipe 145 and formed so that contents in the receptacle is discharged at the small-diameter pipe 145, and a container 200 which is installed at the bottom of the small-diameter pipe 145 and has an open upper part to hold additives therein; a heat-resistant sealing plate 220 configured to heat-seal the insertion pipe 120 and upper wall of the container 200; a sealing plate holder 300 which is provided with a fitting ring 310 that fits the sealing plate 220 to a corresponding part for coupling the heat-resistant sealing plate 220, and which is fitted at an upper end of an inner side wall of an outer cap 400; and the outer cap 400 having a sealing plate holder fixing step 420 which is formed on a side wall 401 and configured to separate the sealing

Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.